Castle Biosciences (CSTL) Assets (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Assets data on file, last reported at $547.8 million in Q1 2026.

• Quarterly Assets rose 9.19% year-over-year to $547.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $547.8 million (up 9.19% YoY) and the FY2025 annual result came in at $578.6 million, up 8.91% from the prior year.
• Assets slipped to $547.8 million in Q1 2026 per CSTL's latest filing, from $578.6 million in the prior quarter.
• The five-year high for Assets was $578.6 million in Q4 2025, with the low at $425.4 million in Q2 2023.
• Average Assets over 5 years is $486.9 million, with a median of $458.5 million recorded in 2024.
• Year-over-year, Assets declined 7.19% in 2023 and grew 18.01% in 2024.
• Castle Biosciences' Assets stood at $447.3 million in 2022, then grew by 1.34% to $453.3 million in 2023, then rose by 17.18% to $531.2 million in 2024, then climbed by 8.91% to $578.6 million in 2025, then declined by 5.32% to $547.8 million in 2026.
• Business Quant data shows CSTL's Assets at $547.8 million in Q1 2026, $578.6 million in Q4 2025, and $562.8 million in Q3 2025.